Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System.
The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs.
Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FDA that underscores the quality of data that Axonics has submitted to the agency. Given this approval, we are confident that this capability will be included as part of the Axonics SNM System premarket approval (“PMA”) approval, which is anticipated in the second half of 2019.”
The Axonics System1 is the first rechargeable SNM system approved for sale in Europe, Canada and Australia and is currently under PMA review by the FDA. Axonics offers a long-lived miniaturized neurostimulator that is approximately the size of a USB stick and is qualified to last at least 15 years in the body, as compared to the only competitive device on the market from Medtronic, which requires replacement every 3 to 5 years. The Axonics System also features many other differentiating attributes, including a patented tined lead, a wireless charging system optimized for infrequent charging, a key fob size easy-to-use patient remote control and an intuitive clinician programmer that facilitates lead placement and stimulation programming.
About Overactive Bladder and Sacral Neuromodulation
Overactive bladder (OAB) includes urinary urge incontinence and urinary frequency and affects an estimated 85 million adults in the U.S. and Europe. OAB is caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. SNM therapy is a well-established treatment that has been widely employed to reduce symptoms and restore bladder function and is also employed to treat urinary retention and fecal incontinence. Reimbursement for SNM is well established in the United States and is a covered service in Europe, Canada and Australia.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics System is the first rechargeable sacral neuromodulation system approved for sale in Europe, Canada and Australia and the first SNM system to gain full-body MRI conditional labeling in Europe. For more information, visit the Company’s website at www.axonicsmodulation.com
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.
1 The Axonics r-SNM System is currently under PMA review and is designated as an investigational medical device
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
Investor & Media Contact
Zack Kubow + 1-415-658-6436
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WEYTEC and Raytheon Team Up to Enhance Air Traffic Management Technology21.10.2019 19:23:00 EEST | Press release
WEY Technology (WEYTEC) and Raytheon Company (NYSE: RTN) have signed a teaming agreement to co-develop the next-generation air traffic controller workplaces called Multi-platform ATC Re-hosting Solution, or MARS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005591/en/ ATC Workplaces of the Future (Photo: Business Wire) Today in the U.S., air traffic controllers use Raytheon's Standard Terminal Automation Replacement System, or STARS, to provide safe and efficient aircraft spacing and sequencing guidance for more than 40,000 departing and arriving aircraft daily at both civilian and military airports. WEYTEC brings smart tech to airport command and control centers around the world through the transmission, control, distribution and display of real-time data critical to efficient flight operations. "Our integrated KVM solutions are autonomous, scalable, and IP-based, which makes them ideal for complex multiscreen workp
Tommy Hilfiger Appoints Michael Scheiner as Global Chief Marketing Officer21.10.2019 18:15:00 EEST | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce the appointment of Michael Scheiner as Chief Marketing Officer, Tommy Hilfiger Global, effective October 28, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005511/en/ Michael Scheiner, Chief Marketing Officer, Tommy Hilfiger Global (Photo: Business Wire) Michael has amassed over 15 years of experience at global brands. He joins Tommy Hilfiger from Hollister Co., where he served as SVP, Global Marketing. His work helped to move Hollister into the top 5 brands among teens in Piper Jaffray’s Fall 2019 Taking Stock survey, and supported Hollister’s recognition as a Top Omni-Channel retailer. Michael will utilize his passion and experience to lead TOMMY HILFIGER into a new era of innovative marketing strategies – particularly across digital and experiential platforms – to reach and engage the next generation of consumers. “As one of the wo
Workiva Named Large Software Company of the Year by International Business Awards®21.10.2019 16:03:00 EEST | Press release
Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, has won a Gold Stevie® Award for Company of the Year in the large software company category in The 16th Annual International Business Awards®. The awards were presented at a gala ceremony in Vienna, Austria on October 19. “Workiva is honored to be recognized globally with a Gold Stevie Award,” said Marty Vanderploeg, CEO of Workiva. “We give our employees the freedom and resources they need – backed by our culture of collaboration and inclusion – to help our customers around the world build trust with connected reporting." The International Business Awards are the world’s premier business awards program. A record total of more than 4,000 nominations from organizations of various sizes and industries in 74 nations and territories were submitted this year for consideration in a wide range of categories. More than 250 executives worldwide served as Stevie Awards judges from May through August.
Mavenir Demonstrates Automated Deployment of Cloud-Native 5G Core at MWC LA21.10.2019 16:00:00 EEST | Press release
Mobile World Congress: Mavenir, a US-based Network Software Provider, and the industry's only end-to-end cloud-native vendor for CSPs, announced today its 5G Core platform, which includes a comprehensive set of 5G core functions on a containerized cloud-native platform. The decomposition of functions into these modular units provides the operators the flexibility to scale them independently; scalability and flexibility that wasn’t possible with 4G EPC. Mavenir has invested heavily in developing the 5G Core solution from the ground-up on cloud-native principles that can still be retrofitted on EPCs. The solution encompasses all the major 5G core elements, such as AMF, SMF, UPF, NRF, UDSF, PCF, UDM, UDR, NSSF, AUSF, BSF, N3IWF, SCP, SEPP, and SMSF. All these functions are implemented as micro-services in containers. In addition, Mavenir is also building remaining 5G core functions, NEF, 5G-EIR, NWDAF etc. The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobi
ResMed Introduces AirFit N30, World’s First Tube-Down Nasal Cradle CPAP Mask21.10.2019 16:00:00 EEST | Press release
ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube – a brand-new option for sleep apnea treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005138/en/ ResMed AirFit N30, tube-down nasal cradle CPAP mask (Photo: Business Wire) ResMed’s lightest mask yet, AirFit N30 features an adjustable elastic headgear, plus a nasal cradle cushion that sits under the nasal bridge, eliminating soreness in that area. The mask’s curved cushion is designed to provide a secure seal regardless of how the wearer sleeps or moves. Together, these innovations help make starting and staying on CPAP therapy easier than ever for more of the 936 million people worldwide living with sleep apnea. “AirFit N30 is about ease of use, helping people ease into therapy and addressing the most common pain points for longtime users,” said Jim Hollingshead, president of R
STELARA® (ustekinumab) Data Demonstrate Long-term Efficacy and Safety Results in Adults With Moderately to Severely Active Ulcerative Colitis in Phase 3 Extension Trial21.10.2019 15:12:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of the Phase 3 UNIFI study, demonstrating the efficacy and safety of ustekinumab through two years of treatment in adults with moderately to severely active ulcerative colitis (UC). These data are being presented today as a late-breaking data presentation (LB01) at the 27th UEGW congress.1 These data include 399 participants who were in clinical response eight weeks after receiving a single intravenous (IV) induction dose of ustekinumab and who were then randomised to receive ustekinumab subcutaneous (SC) 90 mg injections every 12 weeks (q12w), ustekinumab SC 90 mg injections every 8 weeks (q8w), or placebo, and who were treated in the long-term extension.1 Results showed that the majority of patients were able to sustain remission through to week 92 as assessed by symptomatic remission. The percentage of patients receiving ustekinumab SC who were in symptomatic remi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom